Renal Diseases / Nephrology
Showing all 3 results
-
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $5.2 billion by 2030. -
Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030
$6,500.00 – $19,500.00Select optionsGrowth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach $13 billion by 2030. -
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Select optionsCurrently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.